T. Rowe Price Associates
HIMS icon

T. Rowe Price Associates’s Hims & Hers Health HIMS Stock Holding History

T. Rowe Price Associates’s Portfolio HIMS Stock Details HIMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.4M Buy
1,417,344
+690,857
+95% +$16.3M ﹤0.01% 935
2025
Q4 		$23.6M Sell
726,487
-2,341,642
-76% -$100M ﹤0.01% 1023
2025
Q3 		$174M Buy
3,068,129
+2,504,252
+444% +$128M 0.02% 493
2025
Q2 		$28.1M Sell
563,877
-84,895
-13% -$3.84M ﹤0.01% 884
2025
Q1 		$19.2M Buy
648,772
+228,424
+54% +$8.49M ﹤0.01% 966
2024
Q4 		$10.2M Buy
420,348
+312,908
+291% +$7.75M ﹤0.01% 1149
2024
Q3 		$1.98M Sell
107,440
-87,997
-45% -$1.58M ﹤0.01% 1641
2024
Q2 		$3.95M Buy
195,437
+27,010
+16% +$449K ﹤0.01% 1293
2024
Q1 		$2.61M Buy
168,427
+118,848
+240% +$1.34M ﹤0.01% 1450
2023
Q4 		$442K Buy
49,579
+2,922
+6% +$21.6K ﹤0.01% 2230
2023
Q3 		$294K Sell
46,657
-21,875
-32% -$163K ﹤0.01% 2342
2023
Q2 		$645K Sell
68,532
-28,489
-29% -$282K ﹤0.01% 2017
2023
Q1 		$963K Buy
97,021
+35,748
+58% +$313K ﹤0.01% 1807
2022
Q4 		$393K Sell
61,273
-9,507
-13% -$54.1K ﹤0.01% 2252
2022
Q3 		$395K Buy
70,780
+20,099
+40% +$121K ﹤0.01% 2247
2022
Q2 		$230K Buy
50,681
+11,581
+30% +$49.4K ﹤0.01% 2542
2022
Q1 		$208K Hold
39,100
– – ﹤0.01% 2698
2021
Q4 		$256K Buy
+39,100
New +$283K ﹤0.01% 2663

Other funds holding HIMS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DE
Defiance ETFs New York $6.98B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates's HIMS Position: Q1 2026 in Review

T. Rowe Price Associates increased its Hims & Hers Health (HIMS) stake by 95% in Q1 2026, buying an estimated $16.3M and bringing the position to 1,417,344 shares worth $29.4M. The position accounts for ﹤0.01% of the portfolio, ranked #935.

T. Rowe Price Associates first reported a position in HIMS in Q4 2021 and has held it in 18 quarters since. The position peaked at $174M in Q3 2025. 434 funds tracked by Wall St. Rank hold HIMS as of Q1 2026.

  • T. Rowe Price Associates held 1,417,344 shares of Hims & Hers Health worth $29.4M as of Q1 2026.
  • T. Rowe Price Associates bought 690,857 Hims & Hers Health shares in Q1 2026, an estimated $16.3M.
  • Hims & Hers Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #935 holding.
  • T. Rowe Price Associates first reported a position in Hims & Hers Health in Q4 2021 and has held it in 18 quarters since.
  • T. Rowe Price Associates's Hims & Hers Health position peaked at $174M in Q3 2025.
  • 434 funds tracked by Wall St. Rank held Hims & Hers Health as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.